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S U M M A R Y
Objectives: There are currently 94 known pneumococcal capsular polysaccharide serotypes and their
prevalence differs by geographic region and the period studied. Streptococcus pneumoniae infections
have been diagnosed clinically in Trinidad and Tobago and other Caribbean countries, however data on
the serotype and sequence type distributions in this country are limited. The objective of this study was
to determine serotypes and multilocus sequence types (MLSTs) of invasive and non-invasive
pneumococcal isolates from Trinidad and Tobago.
Methods: Ninety-eight pneumococcal isolates from several regional hospitals in the country were
analyzed using both standard microbiological methods and molecular analysis. These isolates included
invasive (n = 83) and selected non-invasive (n = 15) strains recovered before (n = 25) and after (n = 73)
the introduction of the pneumococcal conjugate vaccine.
Results: More than half of the isolates (54.1%) were recovered from children under 15 years of age, with
the largest proportion being from children under 2 years of age (24.5%). The most prevalent serotypes
were 19F (18.4%), 6B (15.3%), 23F (14.3%), 3 (11.2%), 19A (6.1%), 6A (5.1%), 14 (5.1%), and 9V (4.1%).
The most common serotype/MLST combinations were 6B/ST138 (n = 10, 10.2%), 3/ST180 (n = 5, 5.1%),
23F/ST629 (n = 5, 5.1%), 19F/ST8398 (n = 4, 4.1%), and three each of 6B/ST145, 14/9V/ST156, 9V/ST162,
19A/320, and 3/ST10440.
Conclusions: This report provides the ﬁrst glimpse of the prevailing pneumococcal sequence types
in the country. Most of the isolates represented serotypes in the 10-valent (61.2% of isolates) and
13-valent (83.7%) pneumococcal conjugate vaccines. A detailed population study is warranted to
fully determine the circulating pneumococcal sequence types. Furthermore, the implementation
of an effective and continuous surveillance system in Trinidad and Tobago is paramount to monitor
vaccine impact.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Streptococcus pneumoniae continues to be a major cause of
morbidity and mortality in humans.1–3 The spectrum of
pneumococcal disease ranges from a mild respiratory illness
to more severe diseases such as pneumonia and invasive
pneumococcal diseases (IPD) such as bacteremia, sepsis, and
meningitis. Pneumococcal disease is particularly common in* Corresponding author. Tel.: +1 868 645 3232 ext. 2332; fax: +1 868 663 3797.
E-mail address: peakpaka@yahoo.co.uk (P.E. Akpaka).
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1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).young children under 2 years of age and adults over 65 years of
age.1,4
There are currently 94 recognized capsular polysaccharide
serotypes, including the recently reported serotypes 6C, 6D, 11E,
and 20A/20B.2 Each serotype is distinguished based on the
chemical composition of and antigenic differences in the capsular
polysaccharide.2,3 Global surveillance has shown that only a
limited number of capsular serotypes cause more than 70–80% of
IPD.4–6 The serotype distribution of IPD isolates differs somewhat
by geographic region and the time period studied.4–6
Currently, there are two types of pneumococcal vaccine
available on the global market: the pneumococcal polysaccharideciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Pneumovax, Merck) and the pneumococcal conjugate vaccine (10-
valent PCV10 and 13-valent PCV13).3,5 PPV23 is recommended for
use in the elderly and immune-compromised individuals over the
age of 2 years, while the PCVs are recommended for children under
2 years and also for older children. In late 2011, PCV13 was also
recommended for adults 50 years who are clinically at risk,
including adults over 65 years of age.2–4,7,8 PCV7 was formulated to
include the most frequent serotypes causing pediatric IPD at that
time in developed countries, in particular the USA (serotypes 4, 6B,
9V, 14, 18C, 19F, and 23F).3,4,6,9 Two PCVs are currently available
for use in children, PCV10 (PCV7 serotypes plus 1, 5, and 7F; PHiD-
CV, Synﬂorix, GlaxoSmithKline) and PCV13 (PCV7 serotypes plus 1,
3, 5, 6A, 7F, and 19A; Prevnar, Pﬁzer); these replaced PCV7.3,4,7,8
The current vaccines provide wider serotype coverage than the
previous PCV7 formulation.2,3,10
In the Caribbean, as well as other regions, vaccine uptake has
been variable despite its approval for use. Although PCV7 was
introduced in the USA in 2000, it was not until March 2010 that it
was introduced into the national immunization program (NIP) in
Trinidad and Tobago for infants at risk of pneumococcal disease,
mainly those with immune deﬁciencies and other chronic diseases.
Prior to 2010, PCV7 was only available in the private sector for
certain children with medical conditions that put them at higher
risk of disease.11 In 2011, the PCV10 vaccine was introduced,
followed by its widespread use in the NIP for all children aged <2
years.11–13 Subsequently, PCV13 was introduced into the NIP in
August 2015, replacing PCV10. Vaccine coverage with PCV10 was
reported to be 95% as of December 2014.14
PPV23 was licensed in Trinidad and Tobago in 2004, but was
only incorporated into the NIP in 2012 for children over 2 years of
age with chronic diseases, adults 65 years and above, and persons
at risk of pneumococcal disease, including those with HIV/
AIDS.13,14 Trinidad and Tobago does not qualify for donor support
under the Global Alliance for Vaccines and Immunizations (GAVI)
program.15 However, vaccines are provided by the Trinidad and
Tobago Government under their immunization program and are
purchased through a Pan American Health Organization (PAHO)
revolving fund.13
Although pneumococcal infections are clinically diagnosed and
S. pneumoniae are routinely isolated from specimens, data on the
serotype distribution in the Caribbean, and in Trinidad and Tobago
in particular, are limited.11–13,16–23 The use of molecular methods
to determine genotypes of strains in the Caribbean, as in many
Latin American countries, has been limited due to ﬁnancial
constraints and other logistical difﬁculties.24 To the best of the
authors’ knowledge, there is no published study that has used
multilocus sequence typing (MLST) to characterize pneumococcal
isolates from Trinidad and Tobago. The objective of this study was
to characterize pneumococcal isolates from both invasive and
selected non-invasive sites using serotyping and MLST, and to
compare these genotypes to well-described international clonal
complexes (http://www.pneumogen net/pmen/).25
2. Materials and methods
2.1. Bacterial isolates and country demographics
All pneumococcal isolates (n = 73) obtained from routine
clinical specimens submitted to the microbiology diagnostic
laboratories of the ﬁve major public hospitals in Trinidad and
Tobago, during the period 2011 to 2013, were included in this
study. The isolates were included in the analysis if they met the
following selection criteria: (1) patients with evidence of ongoing
infection or conﬁrmed diagnosis (clinical features including fever,
elevated C-reactive protein, and elevated white cell count); (2) S.pneumoniae as the only pathogen isolated from both invasive and
non-invasive sites. Duplicate isolates from the same episode of
infection in any one patient were considered to represent the same
episode, and therefore were counted once. Selected isolates from
non-invasive sites were also included to ascertain a comprehensive
picture of the molecular characteristics of pneumococcal infec-
tions.
A number of historical pneumococcal isolates (n = 25) from
clinical specimens that were collected between 1997 and
2010 were also included in the analysis. Most of the strains were
collected from three regional hospitals, prior to the commence-
ment of the SIREVA (Sistema Regional de Vacinas), the Regional
System for Vaccines in the Americas project in Trinidad and
Tobago.11,26,27 These historical isolates were included to give some
idea of the serotypes and sequence types present in the country
prior to the introduction of the PCV7 in the vaccination program in
Trinidad and Tobago. The isolates from the earlier period (1997–
1998) were not part of a speciﬁc study. The pre- and post-
vaccination periods were deﬁned as the years 1997 to February
2010 and March 2010 to 2013, respectively.
Demographic and clinical parameters were obtained using a
standardized questionnaire. Conventional phenotypic identiﬁca-
tion was performed at the microbiology laboratories of the regional
hospitals in the country. The twin islands of Trinidad and Tobago
are the most southern islands in the Caribbean, located just seven
miles off the north eastern coast of Venezuela, and have an
estimated population of 1.3 million. It is estimated that 19.4% of
the population are less than 14 years old and 9.5% are 65 years old
and above. About 13.7% of the population live in urban areas, with
66 000 people in the major capital city of Port of Spain. The
majority (68.6%) of the population comprises people of African and
Indian descent (34.2% and 34.4%, respectively), with people of
mixed race, European, Chinese, and Middle Eastern ancestry
adding diversity to the ethnic mix.28
All conﬁrmed pneumococcal strains were collected and stored
in brain–heart infusion broth with glycerol at 70 8C until further
conventional and molecular analysis.
Ethical approval was obtained from the Ethics Committee of the
University of the West Indies at St. Augustine. Permission was also
granted by the ethics committees of all the regional hospitals
where the studies were carried out, namely the North West
Regional Health Authority, North Central Regional Health Authori-
ty, Eastern Regional Health Authority, South West Regional Health
Authority, and Scarborough General Hospital Tobago. Patient
records and information were anonymized and de-identiﬁed prior
to analysis.
2.2. Capsular serotyping
All isolates were serotyped by conventional Quellung reaction
method at the US Centers for Disease Control and Prevention (CDC)
Streptococcus Laboratory (CDC, Atlanta, GA, USA). Further
serotyping was performed using a sequential multiplex PCR
method, as described by Pai et al., and updated on the CDC
Streptococcus Laboratory website.29,30 Genomic DNA was
extracted from the bacterial isolates using Chelex 100 (Bio-Rad
Laboratories, Hercules, CA, USA).
2.3. Multilocus sequence typing analysis
MLST was performed as described by Enright and Spratt, with
modiﬁed primers (http://www.cdc.gov/streplab/alt-mlst-pri-
mers.html).31 Brieﬂy, the internal fragments of seven housekeep-
ing genes (aroE, gdh, gki, recP, spi, xpt, and ddl) of the pneumococcal
genome were ampliﬁed and sequenced, then the sequence types
(STs) were determined by comparing the sequences with alleles
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spneumoniae/). New alleles and STs were submitted to the
database curator for assignment. Clonal complexes were deﬁned
as groups of STs sharing 5 alleles with one or more members of
the set and were assigned using eBURST version 3 program (http://
eburst.mlst.net) and arbitrarily assigned CC1–CC13.
3. Results
3.1. Bacterial isolates
Ninety-eight S. pneumoniae isolates were obtained; 83 were
invasive isolates (from blood, pleural ﬂuid, cerebrospinal ﬂuid, and
swab from brain tissue) and 15 were non-invasive isolates (ear, eye
swabs, and sputum). Most of the invasive isolates were from blood
(86.7%, 72/83), while the majority of the non-invasive isolates were
from ear swabs (73.3%, 11/15). More than half of the isolates
(54.1%, 53/98) were recovered from children under 15 years of age
(Table 1), with the largest proportion being from children under
2 years of age (24.5%, 24/98). Twenty-ﬁve (25.5%) pneumococcal
isolates were recovered before the introduction of the conjugate
vaccines (1997 to February 2010) and 73 (74.4%) after (March
2010 to 2013).
3.2. Serotype distribution
Twenty-two different serotypes were detected among the
98 isolates. Only eight serogroups/serotypes were represented by
at least four or more isolates (Table 1) and these accounted for
74.4% of the serotypes. These major serotypes included the
following: 19F (18.4%), 6B (15.3%), 23F (14.2%), 3 (11.2%), 19A
(6.1%), 6A (5.1%), 14 (5.1%), and 9V (4.1%). For the historical
isolates (pre-PCV7 period, 1997–2010), the most prevalent
serotypes in descending order were 19F (n = 7), 3 (n = 5), 6B
(n = 4), 9V (n = 4), and 23F (n = 2); 7.1% were non-vaccine types
(NVT). In the post-PCV7 period (March 2010 to 2013), serotypes
19F, 23F, 6B, 3, 19A, and 6A were the most common, and 32.6%
were NVT. Six serotypes (3, 6B, 11A, 14, 19F, and 23F) were
identiﬁed in both periods. The total coverage rates of PCV7, PCV10,
and PCV13 were 60.2%, 61.2%, and 83.7%, respectively; there was a
signiﬁcant 22.5% difference between PCV10 and PCV13 in
coverage.
3.3. Clonal structure
The 98 pneumococcal isolates included in this study repre-
sented 55 different STs (Table 2). Nine STs accounted for more than
39.7% of the isolates, including ST138 (n = 10), ST180 (n = 5), ST629Table 1
Age and serotype distribution of invasive and non-invasive pneumococcal isolates
from Trinidad and Tobago
Age (years) No. of
isolates (%)
Serotype (No. of isolates)
<2 24 (24.5%) 6B (6), 9V (2), 14 (1), 19F (8), 23F (2),
3 (1), 10A (2), 16F (1), 22F (1)
2 to <5 18 (18.4%) 6B (4), 19F (3), 23F (5) 6A (2), 19A (3), 15C (1)
5 to <15 11 (11.2%) 14 (1), 19F (2), 23F (3), 3 (1), 6A (1),
15C (1), 18C (1)
15 to <24 1 (1.0%) 11A (1)
24 to <45 15 (15.3%) 9V (2), 6B (1), 14 (2), 19F (3), 23F (1), 3 (1),
19A (1), 11A (1), 15A (1), 17F (1), 35F (1)
45 to <60 11 (11.2%) 6B (2), 14 (1), 23F (2), 7F (1), 3 (2), 6A (1),
19F (1), 20 (1), 11A (1)
>60 18 (18.4%) 4 (1), 6B (2), 18C (1), 19F (1), 23F (1), 3 (6),
6A (1), 19A (2), 9N (1), 15B (1), 15A (1)(n = 5), ST8398 (n = 4), and ST145, ST156, ST162, ST320, and
ST10440 (each accounting for three isolates). Fifteen (15.3%) new
STs, including six new MLST alleles, were identiﬁed in this study
and were assigned to ST 9743–9751, 10439, 10440, 10446, 10449,
10450, and 10455 (Table 2). When compared with STs that have
previously been deposited in the MLST database, eight of the
15 were related to previously reported STs. Of these 15 new STs,
eight were identiﬁed during the period 1997–2009, including
ST10440, which was also found during the post-vaccination period
(2011–2013).
STs that represented more than one serotype included ST138
(6A, 6B, 19F), ST156 (9V, 14), and ST199 (15B, 19A). Twelve
serotypes (4, 7F, 9N, 10A, 15A, 15B, 15C, 16F, 17F, 18C, 22F, 35F)
were associated with a single ST, whereas the remaining serotypes
consisted of multiple STs. Serotypes 19F and 23F showed the most
genetic diversity with 14 and eight STs, respectively. Four STs were
isolated during both the pre- and post-PCV periods: STs 62, 156,
180, and 10440. The eBURST analysis revealed 14 clonal complexes
(CC) and 17 singletons containing 63 and 35 isolates, respectively
(Table 2). Of the new STs, ﬁve were singletons and 10 grouped into
CCs. Fourteen isolates (14.3%) were identiﬁed as being related to
seven of the internationally described Pneumococcal Molecular
Epidemiology Network (PMEN) clones (PMEN3, PMEN4, PMEN14,
PMEN31, PMEN37, PMEN38, and PMEN39; http://www.
pneumogen.net/pmen/) (Figure 1).25
4. Discussion
This study aimed to describe the observed prevailing serotypes
and genotypes of pneumococcal isolates from both invasive and
non-invasive pneumococcal diseases in Trinidad and Tobago. IPD is
not a notiﬁable disease in Trinidad and Tobago, and the current
laboratory-based surveillance system is based on voluntary rather
than mandatory submission of isolates. The annual burden of
pneumococcal disease in Latin America and the Caribbean has been
estimated to be 1.6 million in children less than 5 years of age.32 In
Trinidad and Tobago, the incidence rates of fever and acute
respiratory infections (ARI) during the years 2009–2010 in ages
less than 5 was 22 407–25, 202 cases per 100,000 and for ages over
5 years, it decreased from 2447–1163 cases per 100,000 for the
same corresponding years.13
A number of pneumococcal infections in both children and
adult patients were identiﬁed during the two time periods, before
(1997 to February 2010) and after (March 2010 to 2013) PCV
vaccination. A total of 98 isolates were available for analysis, with
the majority recovered during the years 2011–2013. There were
only 25 isolates available for the period 1997–2010 (21 from 1997–
1999 and four from 2007–2010), representing less than 2% of the
pneumococcal isolates reported between 2007 and 2010.11–13,20,21
The majority of the isolates collected during these periods were not
available for the current study analysis due to non-viability after
storage. This is unfortunate, because it was a missed opportunity to
further characterize samples prior to 2010.
The coverage rates of PCV7, PCV10, and PCV13 for pneumococcal
isolates encountered in this study were 60.2%, 61.2%, and 83.7%,
respectively. The observed 22.5% difference in PCV10 and PCV13
coverage rates is noteworthy. PCV10 provided little added beneﬁt to
PCV7, as two of the three serotypes (1 and 5) were rare in Trinidad
and Tobago,11–13,16–22whereas the additional serotypes in PCV13 (3,
6A, and 19A) contributed to the increase in vaccine coverage that
was observed. Data published by the SIREVA network and the
Caribbean Public Health Agency (CARPHA), formerly the Caribbean
Epidemiology Centre (CAREC), have shown that the most prevalent
serogroups/serotypes causing IPD in the Caribbean prior to the NIP
in Trinidad and Tobago were 14, 6B, 23F, 18, 19, 19F, 9, 6A, 1, and
23.16–20,22 Subsequently, serogroups 19 and 9 were identiﬁed as 19F
Table 2
Distribution of genotype (ST) among the pneumococcal serotypes from Trinidad and Tobago, 1997–2013
Serotype No. of isolates Sequence type (No. of isolates) MLST_aroe-gdh-gki-recp-spi-xpt-ddl Clonal complex
4 1 205 10-5-4-5-13-10-18 Singleton
6B 15 138 (8)
145 (3)
146 (2)
497 (1)
4241 (1)
7-5-8-5-10-6-14
7-6-1-1-6-15-14
7-6-1-2-6-15-14
7-25-4-2-48-20-28
15-16-19-10-6-20-26
Singleton
5
5
12
Singleton
9V 4 156 (1)
162 (3)
7-11-10-1-6-8-1
7-11-10-1-6-8-14
2
2
14 5 156 (2)
554 (2)
10449 (1)
7-11-10-1-6-8-1
8-8-4-15-39-12-26
7-11-10-1-451-8-1
2
Singleton
2
18C 2 496 42-35-29-36-9-39-18 13
19F 18 138a (1)
236 (1)
425 (1)
485 (2)
4251 (1)
793 (1)
3907 (1)
6937 (1)
9743 (1)
9744 (1)
9746 (1)
9748 (1)
8398a (4)
10450 (1)
7-5-8-5-10-6-14
15-16-19-15-6-20-26
1-5-1-5-1-1-8
1-5-1-1-1-1-8
15-16-19-10-6-20-26
7-13-9-1-6-19-14
1-5-214-12-1-79-8
2-5-4-5-27-20-5
1-5-106-12-10-4-14
15-16-19-15-6-4-26
18-43-4-1-6-4-8
18-5-4-1-6-11-8
7-11-10-1-8-8-1
327-5-4-5-27-20-5
Singleton
3
6
6
3
11
Singleton
9
Singleton
3
10
10
2
9
23F 14 36 (2)
37 (1)
439 (1)
629 (5)
9747 (1)
9749 (1)
9751 (1)
10446 (2)
1-8-4-1-1-4-6
1-8-6-2-6-4-6
1-8-9-2-6-4-6
1-8-9-10-6-4-6
2-13-2-4-9-1-1
1-8-9-6-6-4-6
1-2-9-10-6-4-6
1-8-9-294-6-4-6
Singleton
1
1
1
4
1
1
1
7F 1 191 8-9-2-1-6-1-17 Singleton
3 11 180 (5)
1116 (1)
662 (1)
10440 (3)
10455 (1)
7-15-2-10-6-1-22
1-26-28-11-13-1-14
5-35-29-12-9-39-18
1-26-28-11-452-1-14
2-12-19-1-6-615-22
Singleton
14
13
14
Singleton
6A 5 473 (2)
138 (1)
460 (1)
490 (1)
7-25-4-4-15-20-28
7-5-8-5-10-6-14
5-7-4-10-10-1-27
2-13-9-1-6-19-14
12
Singleton
7
11
19A
9N
6
1
320 (3)
695 (2)
199 (1)
66
4-16-19-15-6-20-1
16-13-4-4-6-113-18
8-13-14-4-17-4-14
2-8-2-4-6-1-1
3
Singleton
Singleton
4
10A 2 4753 5-241-4-2-10-1-27 7
11A 3 62 (2)
9750 (1)
2-5-29-12-16-3-14
2-5-29-12-16-1-14
8
8
15A 2 73 2-13-2-15-6-1-1 4
15B 1 199 8-13-14-4-17-4-14 Singleton
15C 2 1262 7-41-2-6-10-26-1 Singleton
16F 1 10439 1-10-62-10-15-1-31 Singleton
17F 1 392 7-5-1-1-6-31-14 5
20 1 9745 5-31-8-295-9-1-665 Singleton
22F 1 433 1-1-4-1-18-58-17 Singleton
35F 1 498 2-7-4-16-10-40-27 Singleton
STs underlined refer to new STs identiﬁed in this study. New alleles in this study are in bold.
a These serotype 19F isolates are wzy variants described by Pimenta et al.48
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Bogota´, Colombia.22 During the same period in Trinidad and Tobago,
12 different serogroups and 22 serotypes were identiﬁed, the most
prevalent being 14, 6B, 4, 6A, and 15C. Serotypes 14, 6B, 23F, and
4 were recovered from children under 5 years of age.16–20,23 When
compared globally to those observed in Latin America, North
America, and Europe, the 10 prevalent serotypes prior to 2010 in the
present study were comparably well represented in samples from
elsewhere in the pre-PCV7 and early post-PCV7 eras.2,5,6,9,22,26,33–37Serotypes 1 and 5 were absent during the period 1997–2013 in
the present analysis. This is similar to North America, where
serotypes 1 and 5 are uncommon, but is different from the
situation in some European, Asian, and Latin American countries,
where they are frequently isolated.5,6,9,26,34,36–39 Serotype 6C,
which has been identiﬁed in some countries,40–43was absent in the
isolates tested in the present study. It is unclear whether 6C may
have been among the serogroup 6A/6B isolates reported by CAREC
from 1997 to 1999 and 2007 to 2010, especially among those
Figure 1. eBURST diagram showing a population snapshot of 98 isolates from Trinidad and Tobago with complete MLST data. Each ST is represented by a point, with the size of
the point representing the number of isolates associated with that ST within the dataset. Isolates (14.3%) were related to seven of the internationally described PMEN clones
(http://www.pneumogen.net/pmen/). STs circled represent new STs identiﬁed among isolates in this study.
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USA have shown that previously typed 6A isolates recovered after
PCV7 introduction were primarily 6C.40 Serotype 6C was ﬁrst
described in 2006, however retrospective analyses have indicated
that it was in existence as early as 1962. Prior to PCV7, 6C was
extremely rare in children <5 years old and was uncommon in
adults.40–42,44 However, 6C increased overall with time throughout
the 2000s to become the prevalent serogroup 6 serotype within the
US IPD surveillance.45 Serotype 6C emerged more signiﬁcantly in
adults than in children in the USA during this period,45 although
carriage in children was seen to increase.46 Studies in Spain and
other countries have shown similar increases in both children and
adults, but at relatively low levels.42,47
In the present study, 27% of the 19F isolates were identiﬁed as
19F-var on PCR serotyping due to the wzy variant gene, which was
ﬁrst observed in Canada and Brazil.48–50 Identifying this variation
in the serotype is important for accurate serotype determination in
order to measure the impact of the vaccine. In this study, there was
a marginal shift in the serotype distribution, including the
emergence of NVTs in the post-PCV7/10 period, in particular
serotype 19A. The emergence of 19A was observed globally in the
post-PCV7 era, particularly in North America and many Asian
countries.2,3,5,45 However, this serotype was also observed in some
countries in the pre-PCV era.2,36,39 Not all vaccine serotypes
provide cross-protection to other serotypes in the same group, as
in the case of the 19F antigen in PCV7, which provides little or no
protection against 19A.51 The increased use of both PCV10 and
PCV13 in some countries has now resulted in decreases in these
serotypes, including 19A and 7F, but continued increases in NVTs
like 22F and 33F.51,52 In the present study, PCV7 NVT and PCV10
NVT increases in serotypes 3, 6A, serogroup 15, and serotype 11A
were also seen, as has been reported from the USA and other
developed countries.5,53 Now with the implementation of PCV13 in
Trinidad and Tobago, it will be interesting to monitor the NVTs in
the post-PCV13 period to assess changes in serotype due to
increased valency.The genotyping data using MLST showed great diversity among
isolates from Trinidad and Tobago. While 55 different STs were
identiﬁed, these were assigned to only 14 CCs and there were large
numbers of singletons (n = 17). Also, 15.3% of isolates had new STs,
which will provide the ﬁrst MLST-based data for the Caribbean
region. All new STs were from invasive sites, with the exception of
one recovered from a sputum sample. Serotypes 19F and 23F were
more genetically diverse compared to the other serotypes and
were associated with distinct STs, including nine of the new STs.
Carriage studies have demonstrated that 19F, 23F, and other
‘pediatric’ serotypes colonize the nasopharynx for longer periods
as compared to serotypes like 1 and 7F, which colonize for a shorter
duration.2,54,55 Consequently, as they remain longer in the
nasopharynx, there is sufﬁcient opportunity for horizontal gene
transfer between pneumococcal isolates and other nasopharyngeal
organisms, which potentially contributes to this diversity.56
The occurrence of STs consisting of more than two serotypes
due to horizontal transfer of capsule genes has been well
documented,9,31,33 and there were several examples of capsular
switching events in this study: ST138 (6A, 6B, 19F), ST156 (9V, 14),
and ST199 (15B, 19A). Eight STs (138, 180, 629, 8398, 145, 156, 162,
and 10440) accounted for more than 36% of the isolates, and a
number of isolates (14.3%) belonged to well-described interna-
tional PMEN clones (http://www.pneumogen.net/pmen/). Of the
39 STs reported, 10 from Latin American countries and 29 from
North America have been deposited previously in the MLST
database (http://pubmlst.org/spneumoniae/). Some of these STs
have signiﬁcant geographic spread, for example ST138 and ST180
have been found to be present in most regions, including the USA
and some European and Latin American countries.2,24,33,57 ST629
has been observed in the USA30,58 and Germany (described in the
MLST database). Available data on genotypes from Venezuela are
limited, and the MLST database has 29 isolates deposited since
2007. Among these isolates, only three STs (ST320, ST156, and
ST199) were similar to those from the Trinidad and Tobago study.
Four STs were observed in both the pre- and post-vaccination
M. Nurse-Lucas et al. / International Journal of Infectious Diseases 46 (2016) 100–106 105periods (1997 to February 2010 and March 2010 to 2013): ST62,
156, 180, and 10440. ST62 (11A) was isolated both in 1998 and
2012, and this ST has been described in invasive isolates from Spain
and Italy (described in the MLST database).33
When the clonal composition was compared with the USA and
Scotland in the pre- and the early post-vaccination periods,
variations were observed. For instance, serotype 14 was repre-
sented by four STs in the USA and 12 STs in Scotland during the pre-
PCV era, and quite striking was the absence of ST156 in
Scotland.33,37,39 ST156 has frequently occurred worldwide and
was ﬁrst described as serotype 9V; this has subsequently also been
described as serotype 14 and as other serotypes.25,57 Furthermore,
ST156 is often associated with antibiotic resistance and is one of
the well described PMEN clones (Spain9V-ST156, PMEN3) that have
spread globally, including within the Latin America region.25
Isolates belonging to clonal complex 156 (CC156) were also found
to modestly emerge within 19A in the post-PCV period in the
USA.33 It is also interesting to see this very enduring clonal
complex associated with several serotypes in the post-PCV13
era.59 In the present study, ST156 was associated with both
serotype 9V and 14 (commonly found in South America), and
CC156 included closely related ST8398 (19F), ST162 (9V), and
ST10449 (14). PMEN4 (Tennessee23F-ST37) was represented by
nine STs, all of which were restricted to serotype 23F.33
Six isolates were related to the highly successful Taiwan19F-
ST236 (PMEN14) lineage, including ST320 (19A). In the USA, the
ST320 complex was responsible for a dramatic increase in 19A IPD.
19A/ST320 and related 19A strains became the most commonly
recovered strains from IPD during the 2006–2009 post-PCV7 era,
and also constituted the majority of multi-resistant strains during
this period.60 Putative vaccine escape ST695 19A variants (n = 2) of
the non-resistant major PCV7 type 4 strain were also identiﬁed
among the study isolates in the post-PCV7 period.60 Isolates
belonging to other PMEN included serotype 15B and 19A capsular
variant of Netherlands15B-ST199 (PMEN37), serotype 7F PMEN39
(Netherlands7F-ST191), serotype 4 PMEN38 (Sweden4-ST205), and
ﬁve ST180 serotype 3 isolates belonging to Netherlands3-ST180
(PMEN31). ST180 was isolated mainly from adults with IPD and
was present during the pre-vaccination era and continued to
circulate in 2013. One isolate from the pre-PCV7 period was
recovered from a postmortem case in 1998. This ST180 clone is the
major genotype of serotype 3 isolates globally, but independent
lineages among type 3s in this study were also observed. In Europe
and North America, there have been reports of the ST180 clone
associated with invasive diseases and increased mortality.33,37,61,62
ST1262 (15C), which was ﬁrst observed in the USA study,33 was
also seen in the early post-PCV phase in the present study. The STs
associated with 6B (138, 145, 146, 497, and 4241) were also
different from those detected in Latin American countries.57
Some level of marginal shift in the serotype distribution
appeared to be present in this study, including the emergence of
the NVTs that have been observed globally. While data suggest the
presence of a diverse array of genotypes, some well described
global clones and their capsular variants described in other regions
of the world, in particular North America, and mainly the USA, are
also circulating in Trinidad and Tobago. The STs were slightly
different from those in the neighboring Latin American country
Venezuela, probably because the Venezuelan isolates have been
less studied. This information will continue to provide baseline
data for additional studies needed on the molecular characteriza-
tion of pneumococcal isolates, not only in Trinidad and Tobago, but
also throughout the Caribbean region.
One of the limitations of this study was the relatively small
number of isolates used in the analysis, particularly for the pre-
vaccination period (1997 to February 2010), which may not have
reﬂected the true picture of circulating pneumococcal serotypes inTrinidad and Tobago. The isolates were recovered from patients seen
and treated at the regional hospitals and this may have led to a bias
towards the more severe cases. Despite these limitations, the
information obtained from this study provides the ﬁrst insight into
the prevailing genotypes of pneumococcal isolates in the country.
The ﬁndings also suggest that PCV13 could provide greater serotype
coverage than PCV10 for serotypes currently causing IPD in Trinidad
and Tobago. A more detailed population study is required post-
PCV13 introduction in order to obtain a comprehensive picture of
the circulating pneumococcal genotypes in the country.
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